Lung Health

Each and every day, our lungs are directly exposed to external factors in the environment around us. The immune system is constantly working to maintain homeostasis and healthy body function, all while maintaining lung integrity and optimize lung function. Exposure to harmful environmental factors and genetics cause conditions like asthma, chronic obstructive lung disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and occupational respiratory diseases, which affect millions of people around the world with minimal solutions presently available[1]. Immune dysregulation and inflammation are also key components of both infectious and noninfectious pulmonary diseases[3]. Indeed, the immune system plays the most critical role in maintaining lung health.

What problem do patients face?

The cause of various respiratory diseases is commonly either genetic or environmental. While the immune system works around the clock to protect the lungs, prolonged exposure to harmful factors in the environment often lead to deterioration or dysfunction of the lungs. Patients with respiratory diseases feel the effects in everything they do, from exercise and workday tasks to even simply getting out of bed. Symptoms of these diseases are crippling and make everyday life nearly impossible. Presently, the standard of care for many diseases of the lungs does not solve the actual cause. The current standard of care includes treatments like oxygen therapy, steroids, bronchodilators, and pulmonary rehabilitation, which provide minor temporary relief but do not slow or halt the progression of the disease itself, allowing for proliferation and rapid decline in quality of life. 

What is the solution?

Mesenchymal Stem Cells offer an alternative therapy due to their unique ability to regulate the immune system and increase blood flow. While MSCs are able to transform into several cell types according to specific stimuli[4,5], studies suggest that these cells can help modulate the immune system and re-balance inflammation. MSCs can improve the microenvironment, which can help regenerate lung tissue[6,7]. 

When our MSCs are administered intravenously, they reach the lungs immediately. In lungs affected with chronic disease, MSCs appear to promote tissue regeneration, reduction of lung edema, improvement of energy metabolism, protection against microorganisms, and reduction of proinflammatory activity[6,8,10,11,12,13,14]. MSCs may also regenerate damaged tissue and cells, and in both acute and chronic inflammatory lung disease these cells may restore and improve pulmonary function. The remarkable potential of our MSC therapeutics significantly improves physical indicators and overall quality of life. 

In addition to these benefits, patients treated with our precision MSC therapy experience: 

  • Noticeable improvement in their primary complaint
  • Significantly improved lung capacity 
  • Decreased fatigue and reduced breathing difficulties
  • Increased stamina and endurance
  • Less frequent and less severe infections 
  • Increased blood flow
  • Quicker healing and recovery

See if REHEALTH is Right for You

Patients suffering from these debilitating respiratory diseases now have the opportunity for considerable improvement in quality of life and healthspan. At REHEALTH, your health and wellbeing are our top priority. Our team of certified physicians and research staff design a therapeutic approach specific to your individual needs and condition in order to target the areas causing you the most discomfort. 

Join thousands of other patients who have experienced relief they never thought was possible. Schedule a free discovery call and start your journey to recovery today.

"*" indicates required fields

Name*

References

  1. Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020. 9.
  2. 2. Lloyd CM, Marsland BJ. Lung homeostasis: influence of age, microbes, and the immune system. Immunity. 2017. 46:549-61.
  3. 3. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015. 313:1241-9.
  4. 4. Ferreira Cruz F, Macedo Rocco R. The potential of mesenchymal stem cell therapy for chronic lung disease. Exp Rev Resp Med. 2019.
  5. 5. Wecht S, Rojas M. Mesenchymal stem cells in the treatment of chronic lung disease. Respirology. 21:1366-75.
  6. 6. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012. 20:14-20.
  7. 7. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012. 12:383-96.
  8. 8. Akram KM, Samad S, Spiteri MA, et al. Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms. Respir Res. 2013.14:9.
  9. 9. Fang X, Neyrinck AP, Matthay MA, et al. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoieti 1. J Biol Chem. 2010. 285:26211-22.
  10. 10. Paliwal S, Chadhuri R, Agrawal A, et al. Regenerative abilities of mesenchymal stem cells through mitrochondrial transfer. J Biomed Sci. 2018. 25:31.
  11. 11. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects agains acute lung injury. Nat Med. 2012. 18:759-65.
  12. 12. Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies. Front Immunol. 2017. 8:339.
  13. 13. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensores and switchers of inflammation. Stem Cell. 2013. 13:392-402.
  14. 14. Srour N, Thébaud B. Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: a systematic review. Stem Cells Transl Med. 2015. 4. 1500-10.